CAS 641571-10-0 99% API Nilotinib AMN 107 for Anticancer

Quick Details:

Product Name: Nilotinib

Other Name:Nilotinib;AMN 107;Benzamide, 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-;4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4 -pyridin-3-ylpyrimidin-2-yl)amino]benzamide;Nilotinib(TINIBS );4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide;Nilotinib for research;Tasigna

Model No.: ATC-142

CAS No.: 641571-10-0

Molecular Formula: C28H22F3N7O

Molecular Weight:529.52

Stability: N/A

Target:N/A

Appearance: Off-White Solid

Melting Point: N/A

Purity: 99%+

Suitable People: ALl

Product Specifications: Pharmaceutical Grade 

Standard: Qualified

MOQ(Minimum Order Quantity): 10g

Payment: L/C, T/T,

Shipment: EMS, DHL, FedEx, TNT

Packing: Aluminium Foil Bag or as Required    

Brand: Biocar

Origion: Hubei,China  

Export Markets: Global   

Nilotinib is an anti-cancer medication that is used to treat some types of leukemia, specifically Philadelphia chromosome positive chronic myeloid leukemia (Ph + CML). This medication is called a kinase inhibitor, which means that it works to halt the growth and spread of cancer cells. Nilotinib accomplishes this by inhibiting an abnormal protein that is responsible for instructing cancer cells to multiply. With this particular type of cancer, the body manufactures a great deal of abnormal white blood cells. Nilotinib is only prescribed after other cancer treatments, such as imatinib, have been tried and have not been sufficient.

Nilotinib (AMN107, trade name Tasigna), in the form of the hydrochloride monohydrate salt, is a small-molecule tyrosine kinase inhibitor approved for the treatment of imatinib-resistant chronic myelogenous leukemia. Structurally related to imatinib, it was developed based on the structure of the Abl-imatinib complex to address imatinib intolerance and resistance. Nilotinib is a selective Bcr-Abl kinase inhibitor that is 10-30 fold more potent than imatinib in inhibiting Bcr-Abl tyrosine kinase activity and proliferation of Bcr-Abl expressing cells.